Charles Schwab Investment Management Inc. Increases Holdings in Bausch Health Cos Inc. $BHC

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Bausch Health Cos by 4.5%, now owning approximately 1.34 million shares valued at around $8.7 million.
• Analysts have recently adjusted their price targets for Bausch Health, with Royal Bank Of Canada raising it from $8.50 to $10.00 and recommending a "sector perform" rating.
• Director John Paulson significantly boosted his holdings by acquiring over 34 million shares for approximately $312.5 million, increasing his stake by 96.35%.

Charles Schwab Investment Management Inc. raised its stake in shares of Bausch Health Cos Inc. (NYSE:BHC - Free Report) by 4.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,341,999 shares of the company's stock after buying an additional 57,963 shares during the period. Charles Schwab Investment Management Inc. owned about 0.37% of Bausch Health Cos worth $8,700,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Bausch Health Cos by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company's stock valued at $76,152,000 after buying an additional 61,621 shares during the last quarter. Cary Street Partners Financial LLC purchased a new stake in shares of Bausch Health Cos in the 1st quarter worth $27,000. Wealthquest Corp purchased a new stake in shares of Bausch Health Cos in the 1st quarter worth $58,000. XTX Topco Ltd purchased a new stake in shares of Bausch Health Cos in the 1st quarter worth $139,000. Finally, Federated Hermes Inc. purchased a new stake in shares of Bausch Health Cos in the 1st quarter worth $758,000. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have recently commented on BHC shares. Royal Bank Of Canada upped their price objective on Bausch Health Cos from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd. Wall Street Zen upgraded Bausch Health Cos from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat, Bausch Health Cos has an average rating of "Hold" and an average target price of $9.00.

Insiders Place Their Bets

In other news, Director John Paulson acquired 34,721,118 shares of Bausch Health Cos stock in a transaction that occurred on Thursday, August 14th. The shares were bought at an average cost of $9.00 per share, with a total value of $312,490,062.00. Following the transaction, the director directly owned 70,755,869 shares of the company's stock, valued at $636,802,821. This trade represents a 96.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Over the last 90 days, insiders have bought 44,316,834 shares of company stock valued at $369,628,560. Corporate insiders own 8.12% of the company's stock.

Bausch Health Cos Stock Down 2.5%

BHC opened at $7.30 on Tuesday. The firm has a 50-day simple moving average of $6.63 and a two-hundred day simple moving average of $6.03. Bausch Health Cos Inc. has a 52 week low of $4.25 and a 52 week high of $9.85. The company has a market capitalization of $2.70 billion, a PE ratio of 28.08 and a beta of 0.41. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90.

Bausch Health Cos (NYSE:BHC - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.97 by ($0.07). The company had revenue of $2.57 billion for the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos had a net margin of 0.99% and a negative return on equity of 852.36%. Bausch Health Cos has set its FY 2025 guidance at EPS. Analysts forecast that Bausch Health Cos Inc. will post 4.41 earnings per share for the current fiscal year.

Bausch Health Cos Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.